Despite the trial failure, Sarepta will still seek full approval of AMONDYS 45 and VYONDYS 53 in DMD from the FDA.
At the European Society for Medical Oncology (ESMO) 2025 event, held in Berlin, Germany, between 17-21 October, Celcuity ...
AbbVie's Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the non-segmental ...
While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...
In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...
Accurately tracking trial initiations has often been a challenge because start dates are not always disclosed or are reported incorrectly. Credit: Ihar Halavach via Shutterstock.com. According to ...
The company’s stock rose significantly after it announced the full Phase I/II data. Image credit: Lightspring / Shutterstock.com. Intensity Therapeutics’ stock has risen nearly 400% after its oncology ...
The FDA has introduced a new draft guidance, which aims to expedite and simplify the biosimilar approval process, which commissioner Marty Makary noted could result in “massive cost reductions for ...
The trial will investigate the AK0610 injection for the prevention of RSV infection. Credit: QINQIE99 / Shutterstock.com. Shanghai Ark Biopharmaceutical (ArkBio) has commenced a randomised Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback